|
Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon-β treatment in multiple sclerosis patients
Rodica Bălaşa, Adina Huţanu, Camelia Feier, Zoltan Bajko, Ion Pascu
Abstract: Purpose: During interferon (IFNβ) treatment of multiple sclerosis (MS), the therapy induced binding antibodies (BAbs) and neutralizing antibodies might decrease the clinical efficacy of IFNβ. We evaluated: differences in immunogenicity of different IFNβ products using BAbs; the impact of BAbs on clinical efficacy of INFβ. We present the first Romanian experience on this issue. Material and methods: 229 MS patients treated for at least 12 months with either subcutaneous IFNβ-1b 250μg every other day (Betaferon 132 patients), subcutaneous IFNβ-1a 44μg three times a week (Rebif 71patients) or intramuscular IFNβ-1a 30μg once weekly (Avonex, 26 patients) were tested for BAbs using quantitative dELISA. The groups were clinically and demographically alike. According to the results, each group was divided into: 1.BAbs+; 2.BAbs-. Subgroups and titer of BAbs were compared with disability score (EDSS) variation in the last year and number of relapses during IFNβ treatment (Mann-Whitney and Spearman correlation). Results: The percentage of BAbs+ patients was: Betaferon 64.4%, Rebif 18.3%, Avonex 15.4%. In the Rebif group, a correlation was found between presence and value of BAbs and EDSS change (p=0.05) but not with the number of relapses. No correlation was found between the presence or value of BAbs and relapses or EDSS change in Betaferon or Avonex group. Conclusions: (i) Betaferon is more immunogenic than Rebif or Avonex; (ii) BAbs do not abrogate the clinical effects of Betaferon or Avonex regardless the parameter used; (iii) assays for BAbs are relatively inexpensive and have a role in following Rebif treatment.
Keywords: binding antibodies,neutralizing antibodies,multiple sclerosis,immunomodulatory treatment
|
|
|
Bălaşa R, Huţanu A, Feier C, Bajko Z, Pascu I. Incidence and clinical significance of binding antibodies and their relationships with neutralizing antibodies, both induced by interferon-β treatment in multiple sclerosis patients. Rev Romana Med Lab. 2010;18(3):39-50
|